Jupiter Neurosciences, Inc. (JUNS) - 10-K Summary
Business Context and Reporting Period
Company: Jupiter Neurosciences, Inc.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Model: Clinical-stage biopharmaceutical company operating in two segments: (1) Pharmaceutical operations developing JOTROL™ (an enhanced resveratrol formulation) for CNS disorders (Parkinson's, Alzheimer's) and rare diseases; and (2) Premium nutritional supplements under the Nugevia brand launched in late 2025.
Key Milestone: Received FDA IND approval for a Phase IIa Parkinson's Disease trial in November 2025, with first dosing expected in Q2 2026.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Revenue | $21,796 | $0 |
| Net Loss | $(8,644,897) | $(2,439,625) |
| Operating Cash Flow | $(5,413,736) | $(3,911,004) |
| Cash & Equivalents (Year End) | $3,789,342 | $3,769,510 |
| Accumulated Deficit | $(34,667,026) | $(26,022,129) |
| Outstanding Debt (Convertible Notes) | $6,000,000 Principal | $0 |
Note: Revenue in 2025 is derived solely from the Nugevia consumer product line launched in Q4 2025. Gross profit on these sales was $17,565.
Material Changes vs. Prior Period
- Revenue Generation: Transitioned from $0 revenue in 2024 to $21,796 in 2025 following the Q4 launch of Nugevia supplements.
- Expense Surge: Net loss increased by 254% to $8.64 million. General and Administrative (G&A) expenses rose 163% to $6.84 million, driven by increased salaries, investor relations, and professional fees. R&D expenses increased 324% to $2.09 million due to preparations for the Parkinson's Phase IIa trial.
- Debt Structure: Entered a Standby Equity Purchase Agreement (SEPA) with Yorkville in October 2025, issuing $6.0 million in convertible promissory notes (fair value liability of $5.3 million at year-end). This replaced previous debt structures fully repaid in 2024.
- Stock Issuance: Issued 3.5 million shares to Asian service partners in 2024 (amortized expense) and 131,909 commitment shares to Yorkville in 2025.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring significant net losses. The company requires substantial additional capital to fund the Parkinson's Phase IIa trial and commercialize Nugevia. Cash on hand ($3.8M) is insufficient to fund operations through the completion of development and commercialization.
Going Concern: Management and auditors have concluded there is substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
Key Risks:
- Nasdaq Compliance: Received notices in Feb 2026 of non-compliance with minimum bid price ($1.00) and market value of listed securities ($35M) requirements. Has 180 days (until Aug 25, 2026) to regain compliance or face delisting.
- Liquidity: Reliance on the SEPA for liquidity is constrained by low trading volume, which limits the ability to draw funds to repay convertible notes.
- Internal Controls: Identified material weaknesses in internal controls over financial reporting due to inadequate segregation of duties.
- Intellectual Property: Business is critically dependent on an exclusive license with Aquanova for JOTROL™ technology.
Investor Verification Checklist
- Cash Runway: Verify if the $3.8M cash balance is sufficient to fund operations until the next capital raise, given the $6M debt obligation and high burn rate.
- Nasdaq Status: Monitor the company's progress in regaining compliance with Nasdaq listing standards by the August 2026 deadline to avoid delisting.
- SEPA Utilization: Assess the feasibility of utilizing the SEPA given the current low stock price and trading volume constraints.
- Debt Covenants: Review the terms of the $6M convertible notes, specifically the repayment schedule (deferred to April 2026) and conversion mechanics.
- Nugevia Traction: Evaluate the sustainability of the Nugevia revenue stream, which generated only ~$22k in its first quarter of operation.